key: cord-0778377-fvf2m2gw
authors: Khan, Ahmad; Bilal, Mohammad; Morrow, Vincent; Cooper, Gregory; Thakkar, Shyam; Singh, Shailendra; Annie, Frank H.; Mansoor, Emad; Hutson, William
title: Impact of COVID-19 Pandemic on Gastrointestinal Procedures and Cancers in the United States. A Multicenter Research Network Study.
date: 2021-03-01
journal: Gastroenterology
DOI: 10.1053/j.gastro.2021.02.055
sha: 5beea3a0776b0d224e2dad378e044eaa506ff104
doc_id: 778377
cord_uid: fvf2m2gw

nan

Ethics approval: The study was approved by Charleston Area Medical Center, Charleston, WV Institutional Review Board. The study qualified as exempt from review. TriNetX Data has also been granted a waiver from the Western Institutional Review Board (IRB) since it is a federated network, and only aggregated counts and statistical summaries of the de-identified information without any protected health information is received from member HCO's. Figure 1) .

Similarly, a decrease in the patient visits, procedures, and new diagnosis of cancers were also seen in the later phase of the pandemic (July-November 2020) compared to a similar period in 2019; however, the proportion of the decline was smaller compared to early pandemic ( Figure   1 and Supplementary Table 1 ). The decrease in new diagnoses of malignant liver and intrahepatic (25.58%), colorectal (11.74%), esophageal and gastric (19.78%), and pancreatobiliary (15.56%) cancers later in the pandemic was considerable but recovered compared with early COVID-19 pandemic.

Our study including data from multiple health care organizations in the United States showed the collateral damage caused by the COVID-19 pandemic leading to potential delays in the diagnosis of major GI cancers. Patient encounters and new diagnoses of GI cancers and procedures significantly declined during the COVID-19 pandemic compared to a similar period in 2019. Our findings report trends similar to other studies, which showed a reduction in all cancer-related patient encounters during the COVID-19 pandemic [2, 3] . These trends may result in an increase in late-stage cancer cases and poor cancer outcomes; J o u r n a l P r e -p r o o f moreover, the cancellation of cancer preventive GI procedures can lead to a rise in the incidence of GI cancers in the future. An increase in virtual visits was seen, however, the volume of these virtual visits was not large enough to account for the decrease in volume of ambulatory visits, nor the nature of virtual visits could replace procedures or imaging needed for cancer diagnosis.

Decreases in GI procedures is a significant disruption of practice patterns and source of revenue for gastroenterologists. Going forward when GI endoscopy and routine healthcare services are resumed in full capacity, there will be a significant burden and demand for procedures related to cancer screening. An increase in capacity of GI procedures will be needed and gastroenterologists will also have to triage patient panels to evaluate and schedule persons at risk for malignancy sooner carefully. Similarly, gastroenterologists will need to use all available evidence-based required tools for cancer screening. For instance, in patients needing colon cancer screening, using non-invasive screening methods such as FIT, Fecal-FIT DNA, and CT colonography in addition to colonoscopy will be needed [6] . Other experts have also suggested considering weekend and evening endoscopy sessions to meet the backlog of GI endoscopy created during the pandemic[7]. However, this will need to be balanced by the burden on the already strained healthcare system and physician burnout. These factors will become especially crucial in a prolonged COVID-19 pandemic. This will further extend these reported trends and delay in new cancer diagnosis.

Our study has several limitations. The data derived from administrative coding systems has the inherent limitations of miscoding or data entry errors. Our study estimated procedures and diagnosis only among the patients with healthcare encounters and did not account for patient population without healthcare encounters. Differences in cancer staging, histology, treatment modalities and mortality was not determined. Despite these limitations, our study is the largest study that shows a reduction in diagnoses of major GI cancers during the pandemic. This highlights the serious future implications that can result in an increased restraint on healthcare resources and lead to increased morbidity and mortality. Urgent policy and practice interventions will be needed, and healthcare organizations and gastroenterologists will need to use innovative methods to meet the backlog of screening and diagnostic tests for GI cancers.

Coronavirus (COVID-19) outbreak: what the department of endoscopy